AbbVie Inc (ABBV) - Net Assets
Based on the latest financial reports, AbbVie Inc (ABBV) has net assets worth $-3.23 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.96 Billion) and total liabilities ($137.19 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ABBV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.23 Billion |
| % of Total Assets | -2.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.91% |
| 10-Year Change | -169.63% |
| Growth Volatility | 97.16 |
AbbVie Inc - Net Assets Trend (2010–2025)
This chart illustrates how AbbVie Inc's net assets have evolved over time, based on quarterly financial data. Also explore AbbVie Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for AbbVie Inc (2010–2025)
The table below shows the annual net assets of AbbVie Inc from 2010 to 2025. For live valuation and market cap data, see how much is AbbVie Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-3.23 Billion | -195.96% |
| 2024-12-31 | $3.36 Billion | -67.64% |
| 2023-12-31 | $10.40 Billion | -39.86% |
| 2022-12-31 | $17.29 Billion | +11.99% |
| 2021-12-31 | $15.44 Billion | +17.86% |
| 2020-12-31 | $13.10 Billion | +260.27% |
| 2019-12-31 | $-8.17 Billion | +3.24% |
| 2018-12-31 | $-8.45 Billion | -265.71% |
| 2017-12-31 | $5.10 Billion | +9.94% |
| 2016-12-31 | $4.64 Billion | +17.52% |
| 2015-12-31 | $3.94 Billion | +126.46% |
| 2014-12-31 | $1.74 Billion | -61.22% |
| 2013-12-31 | $4.49 Billion | +33.57% |
| 2012-12-31 | $3.36 Billion | -71.82% |
| 2011-12-31 | $11.93 Billion | -24.01% |
| 2010-12-31 | $15.70 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AbbVie Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1549300000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.00 Million | % |
| Other Comprehensive Income | $-1.14 Billion | % |
| Other Components | $13.35 Billion | % |
| Total Equity | $-3.27 Billion | 100.00% |
AbbVie Inc Competitors by Market Cap
The table below lists competitors of AbbVie Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chevron Corp
NYSE:CVX
|
$372.46 Billion |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
$385.82 Billion |
|
Netflix Inc
NASDAQ:NFLX
|
$390.09 Billion |
|
SK hynix Inc
F:HY9H
|
$398.13 Billion |
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
$363.55 Billion |
|
Caterpillar Inc
NYSE:CAT
|
$362.70 Billion |
|
Bank of America Corp
NYSE:BAC
|
$349.79 Billion |
|
Procter & Gamble Company
NYSE:PG
|
$344.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AbbVie Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,325,000,000 to -3,270,000,000, a change of -6,595,000,000 (-198.3%).
- Net income of 4,226,000,000 contributed positively to equity growth.
- Dividend payments of 11,657,000,000 reduced retained earnings.
- Share repurchases of 980,000,000 reduced equity.
- Other comprehensive income increased equity by 781,000,000.
- Other factors increased equity by 1,035,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.23 Billion | +129.24% |
| Dividends Paid | $11.66 Billion | -356.48% |
| Share Repurchases | $980.00 Million | -29.97% |
| Other Comprehensive Income | $781.00 Million | +23.88% |
| Other Changes | $1.03 Billion | +31.65% |
| Total Change | $- | -198.35% |
Book Value vs Market Value Analysis
This analysis compares AbbVie Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $9.66 | $206.60 | x |
| 2011-12-31 | $7.34 | $206.60 | x |
| 2012-12-31 | $2.13 | $206.60 | x |
| 2013-12-31 | $2.80 | $206.60 | x |
| 2014-12-31 | $1.08 | $206.60 | x |
| 2015-12-31 | $2.41 | $206.60 | x |
| 2016-12-31 | $2.84 | $206.60 | x |
| 2017-12-31 | $3.18 | $206.60 | x |
| 2018-12-31 | $-5.46 | $206.60 | x |
| 2019-12-31 | $-5.51 | $206.60 | x |
| 2020-12-31 | $7.82 | $206.60 | x |
| 2021-12-31 | $8.67 | $206.60 | x |
| 2022-12-31 | $9.70 | $206.60 | x |
| 2023-12-31 | $5.84 | $206.60 | x |
| 2024-12-31 | $1.88 | $206.60 | x |
| 2025-12-31 | $-1.83 | $206.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AbbVie Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.91%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (70.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 26.61% | 26.72% | 0.74x | 1.35x | $2.61 Billion |
| 2011 | 28.77% | 19.68% | 0.89x | 1.64x | $2.24 Billion |
| 2012 | 156.85% | 28.70% | 0.68x | 8.03x | $4.94 Billion |
| 2013 | 91.90% | 21.97% | 0.64x | 6.50x | $3.68 Billion |
| 2014 | 101.84% | 8.89% | 0.73x | 15.79x | $1.60 Billion |
| 2015 | 130.39% | 22.50% | 0.43x | 13.45x | $4.75 Billion |
| 2016 | 128.41% | 23.22% | 0.39x | 14.26x | $5.49 Billion |
| 2017 | 104.16% | 18.82% | 0.40x | 13.89x | $4.80 Billion |
| 2018 | 0.00% | 17.36% | 0.55x | 0.00x | $6.53 Billion |
| 2019 | 0.00% | 23.69% | 0.37x | 0.00x | $8.70 Billion |
| 2020 | 35.30% | 10.08% | 0.30x | 11.51x | $3.31 Billion |
| 2021 | 74.91% | 20.54% | 0.38x | 9.51x | $10.00 Billion |
| 2022 | 68.60% | 20.39% | 0.42x | 8.04x | $10.11 Billion |
| 2023 | 46.94% | 8.95% | 0.40x | 13.00x | $3.83 Billion |
| 2024 | 128.66% | 7.59% | 0.42x | 40.65x | $3.95 Billion |
| 2025 | 0.00% | 6.91% | 0.46x | 0.00x | $4.55 Billion |
Industry Comparison
This section compares AbbVie Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $18,267,350,444
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AbbVie Inc (ABBV) | $-3.23 Billion | 26.61% | N/A | $365.30 Billion |
| Amgen Inc (AMGN) | $25.78 Billion | 20.01% | 1.68x | $177.77 Billion |
| Amarin Corporation PLC (AMRN) | $667.10 Million | 1.16% | 0.60x | $292.71 Million |
| AstraZeneca PLC (AZN) | $23.95 Billion | 26.05% | 1.24x | $286.40 Billion |
| Biogen Inc (BIIB) | $5.81 Billion | 13.49% | 0.46x | $27.45 Billion |
| Bristol-Myers Squibb Company (BMY) | $12.21 Billion | 42.98% | 1.42x | $118.52 Billion |
| Gilead Sciences Inc (GILD) | $1.87 Billion | 24.02% | 0.15x | $163.34 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $8.32 Billion | 55.33% | 3.74x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $70.42 Billion | 23.49% | 1.01x | $547.37 Billion |
| Eli Lilly and Company (LLY) | $15.39 Billion | 15.53% | 1.36x | $862.20 Billion |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more